Novel Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease: What Cardiologists and Diabetologists Should Know
Main Author: | Felipe Martínez |
---|---|
Format: | Article |
Language: | English |
Published: |
Radcliffe Medical Media
2021-03-01
|
Series: | European Cardiology Review |
Online Access: | https://www.ecrjournal.com/articleindex/ecr.2020.38 |
Similar Items
-
Cardiologist and Diabetologist crosstalk in the era of cardiovascular outcome trials of novel glucose-lowering drugs
by: Francesco Maranta, et al.
Published: (2018-12-01) -
What Every Diabetologist Should Know about SARS-CoV-2: State of Knowledge at the Beginning of 2021
by: Urszula Abramczyk, et al.
Published: (2021-03-01) -
Diabetes, Endothelial Dysfunction, and Vascular Repair: What Should a Diabetologist Keep His Eye on?
by: V. Altabas
Published: (2015-01-01) -
WHAT EVERY CARDIOLOGIST SHOULD KNOW ABOUT H1N1?
by: Allahyar Golabchi, et al.
Published: (2010-12-01) -
A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease
by: Tariq Ahmad, et al.
Published: (2021-03-01)